When was Upstream Bio founded?

Upstream Bio was founded in 2021 and raised its 1st funding round 1 year after it was founded.

Where is Upstream Bio located?

Upstream Bio is headquartered in Waltham, United States.

How many employees does Upstream Bio have?

As of Apr 30, 2026, the latest employee count at Upstream Bio is 73.

Is Upstream Bio a funded company?

Upstream Bio is a funded company, having raised a total of $400M across 2 funding rounds to date. The company's 1st funding round was a $***** Series A round, raised on Jun 02, 2022.

When was the latest funding round of Upstream Bio?

Upstream Bio's latest funding was a $***** Series B round on Jun 08, 2023, with participation from 12 investors. Its primary sector is Immunology. In United States, the Immunology sector has seen $2.52B in funding in 2026 to date.

What is the annual revenue of Upstream Bio?

Annual revenue of Upstream Bio is $2.85M as on Dec 31, 2025.

Where does Upstream Bio rank among its competitors?

Upstream Bio ranks 4th amongst 300 active competitors, of which 113 are funded. It stands 2nd in terms of total funding among its competitors. The most recent competitor to raise funding was Evommune, which secured $125M in Feb, 2026.

Who are the top competitors of Upstream Bio?

Upstream Bio's top competitors include Septerna, Evommune and Philogen. Among them, Evommune secured the most recent funding round in February, 2026.

Upstream Bio - 2026 Company Profile, Team, Funding, Competitors & Financials

Upstream Bio is a public company based in Waltham (United States), founded in 2021 by Eran Perry and Oren Becker. It operates as a Developer of therapeutics for allergic and inflammatory diseases. Upstream Bio has raised $400M in funding from investors like Orbimed, Maruho and Venrock. The company has 300 active competitors, including 113 funded and 59 that have exited. Its top competitors include companies like Septerna, Evommune and Philogen.

Company Details

Developer of therapeutics for allergic and inflammatory diseases. The lead candidate for the company UPB-101 is a monoclonal antibody that inhibits the TSLP receptor that affects a variety of immune cells pivotal to many inflammatory diseases.

Website: upstreambio.com
Social
Email ID: *****@upstreambio.com

Key Metrics

Founded Year

2021

Location

Waltham, United States

Stage

Public

Total Funding

$400M in 2 rounds

Latest Funding Round

Series B, Jun 08, 2023, $*****

Investors

Orbimed & 12 more

Ranked

4^th among 300 active competitors

Annual Revenue

$2.85M as on Dec 31, 2025

Employee Count

73 as on Apr 30, 2026

Similar Companies

Septerna & 362 more

Exit Details

Public

View Upstream Bio's full profile

Upstream Bio is associated with 1 legal entity given below:

Legal Entity Name	Date of Incorporation	Revenue	Latest Employee Count	Documents
Upstream Bio, Inc. CIN: 2022626 , United States, Active		$2.85M (As on Dec 31, 2025)	-	-

Upstream Bio got listed on Oct 11, 2024.

Click here to take a look at Upstream Bio's IPO in detail

Upstream Bio has raised a total funding of $400M over 2 rounds. Its first funding round was on Jun 02, 2022. Its latest funding round was a Series B round on Jun 08, 2023 for $*****. 12 investors participated in its latest round. Upstream Bio has 13 institutional investors.

Here is the list of recent funding rounds of Upstream Bio:

Date of Funding	Funding Amount	Round Name	Post-Money Valuation	Revenue Multiple	Lead Investors	Other Investors
Jun 08, 2023	4271402	Series B	4622619	5683258	1951789	7293586
Jun 02, 2022	7033305	Series A	4849650	3302292	Maruho & 1 more	Decheng Capital & 6 more

Access funding benchmarks and valuations. Sign up today!

View details of Upstream Bio's funding rounds and investors

The founders of Upstream Bio are Eran Perry and Oren Becker.

Here are the details of Upstream Bio's key team members:

Eran Perry: Former Co-Founder of Upstream Bio and founder of 2 other companies, Mii and ICD Pharma.
Contact Info: 1 email address
Oren Becker: Founder of Upstream Bio and founder of 1 other company.

View details of Upstream Bio's Founder profiles and Board Members

Upstream Bio's employee count trend

Upstream Bio has 73 employees as of Apr 26. Here is Upstream Bio's employee count trend over the years:

Uncover Upstream Bio's growth story! Sign up today!

Access Tracxn on any website

Our Google Chrome extension lets you view company details while browsing their websites

Install Tracxn Extension

Top competitors of Upstream Bio include Septerna, Evommune and Philogen. Here is the list of Top 10 competitors of Upstream Bio, ranked by Tracxn score:

Rank	Company Details	Short Description	Total Funding	Investors	Tracxn Score
1st	Septerna 2020, San Bruno (United States), Public	Developer of GPCR drug discovery platform for multiple diseases	$250M	RA Capital Management, Third Rock Ventures ... & 14 others	71/100
2nd	Evommune 2020, Sacramento (United States), Public	Developer of therapeutic options for chronic inflammatory disorders	$276M	Pivotal bioVenture Partners, RA Capital Management ... & 18 others	69/100
3rd	Philogen 1996, Sovicille (Italy), Public	Developer of antibody based drugs for angiogenesis-related cancer and inflammatory disorders	$69.7M	The Equity Club, Novacapital & 3 others	68/100
4th	Upstream Bio 2021, Waltham (United States), Public	Developer of therapeutics for allergic and inflammatory diseases	$400M	Access Industries, Wellington & 11 others	67/100
5th	Odyssey 2018, Cambridge (United States), Public	Developer of immunotherapeutics for immunological and cancer diseases	$717M	Orbimed, General Catalyst & 29 others	66/100
6th	Ventyx Biosciences 2018, Encinitas (United States), Acquired	Developer of therapeutics to treat autoimmune diseases	$165M	VenBio, Logos Capital & 13 others	66/100
7th	CalciMedica 2006, San Diego (United States), Public	Developer of CRAC channel inhibitor drugs for inflammatory diseases	$76.7M	Biogen, SR One & 10 others	64/100
8th	Inotrem 2013, Paris (France), Series B	Developer of peptide immunotherapies for treating septic shock and acute myocardial infarction	$122M	Morningside, Morningside & 11 others	63/100
9th	Gesynta Pharma 2017, Solna (Sweden), Series B	Developer of oral therapies for treating chronic inflammatory conditions	$31.1M	Industrifonden, Hadean Ventures & 1 others	62/100
10th	Auron Therapeutics 2018, Wellesley (United States), Series B	Developer of cancer therapeutics for the treatment of blood cancer	$118M	Mubadala, Qiming & 11 others	62/100